Regenxbio (RGNX) Current Assets (2014 - 2025)

Regenxbio's Current Assets history runs 12 years deep, the most recent figure standing at $281.3 million for Q4 2025.

• In Q4 2025, Current Assets rose 1.18% year-over-year to $281.3 million; the TTM figure through Dec 2025 stood at $281.3 million (up 1.18% YoY), while the FY2025 annual figure was $281.3 million, up 1.18% from the prior year.
• Current Assets was $281.3 million for Q4 2025 at Regenxbio, down from $332.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $518.8 million in Q4 2021 to a low of $278.0 million in Q4 2024.
• Historically, Current Assets has averaged $386.6 million across 5 years, with a median of $384.0 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Current Assets soared 47.42% in 2021, then slipped 20.78% in 2025.
• A 5-year view of Current Assets shows it stood at $518.8 million in 2021, then declined by 19.82% to $416.0 million in 2022, then fell by 19.47% to $335.0 million in 2023, then decreased by 17.01% to $278.0 million in 2024, then rose by 1.18% to $281.3 million in 2025.
• The last three Current Assets figures came in at $281.3 million (Q4 2025), $332.0 million (Q3 2025), and $373.8 million (Q2 2025), per Business Quant data.